Brazil suspends Mallinckrodt contrast agent
This article was originally published in Clinica
Executive Summary
The Brazilian healthcare surveillance agency, Anvisa, has suspended the use and distribution of Mallinckrodt's Conray contrast agent, after linking the product with at least four cases of "serious adverse reactions". The measure was adopted preventatively, pending the results of an investigation which is currently focusing on a single lot (number H 151 B) of the Conray iothalamate meglumine (60%) injectable ionic agent.